Veracyte: Pay

Veracyte paid its 5 named executives $18.8M in total in FY2025 (Dec). CEO Marc Stapley was paid $7.4M of that.

Pay$100 in the stock at the end of FY21 → $102
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Marc StapleyChief Executive Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)Not disclosed
FY2022 (Dec)Not disclosed
4 years
John LeiteGlobal Chief Commercial Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
3 years
Rebecca ChambersChief Financial Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
5 years
Annie McGuireGeneral Counsel and Head of Market Access
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
4 years
Phillip FebboChief Scientific Officer and Chief Medical Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
3 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 6 peers with pay on file was $11.7M. The CEO of Veracyte was paid $7.4M, 37% below the median.

  1. 1Natera
  2. 2Twist Bioscience
  3. 3GLAUKOS
  4. 4Ultragenyx Pharmaceutical
  5. 5Adaptive Biotechnologies
  6. 6Veracyte
  7. 710x Genomics
  8. 8Amicus TherapeuticsNot disclosed
  9. 9Biocryst PharmaceuticalsNot disclosed
  10. 10CareDXNot disclosed
  11. 11Cytek BiosciencesNot disclosed
  12. 12Exact SciencesNot disclosed
  13. 13Fulgent GeneticsNot disclosed
  14. 14Guardant HealthNot disclosed
  15. 15Maravai LifesciencesNot disclosed
  16. 16Myriad GeneticsNot disclosed
  17. 17NeoGenomicsNot disclosed
  18. 18NevroNot disclosed
  19. 19Pacific Biosciences of CaliforniaNot disclosed
  20. 20VericelNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.